Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026

The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires federal agencies to include reasonable pricing clauses in all research grants and contracts involving biomedical products. Under this provision, U.S. residents cannot be charged more than the median price found in Canada and six other high-income OECD countries for any drug, device, or therapy developed with federal support. The Secretary of Health and Human Services is authorized to establish additional regulations, such as mechanisms to lower prices when revenues exceed targets or costs per health benefit are too high, while retaining the ability to waive these obligations if doing so serves the public interest. To ensure accountability, manufacturers must report clinical trial costs, government subsidies, and annual revenues by county, with all data made publicly available.